BioVie Reports Distinct Biomarker Responses In Phase 2 Long COVID Trial; Stock Down
BioVie Inc. (BIVI) reported distinct biomarker responses in its Phase 2 ADDRESS-LC trial for Long COVID treatment. Two patient groups showed different responses to bezisterim, with high-inflammatory patients improving in cognitive function and low-WBC patients in fatigue and PEM. The stock is down 0.75% to $1.32.
How this was made
The 30-second read
Why it matters
The new biomarker‑defined subgroup data provide early signals of efficacy but also highlight variability, influencing valuation and pipeline expectations.
Market read
First public disclosure of Phase 2 subgroup results; modest price move suggests limited immediate impact but informs longer‑term valuation.
What to watch
Potential for the drug to advance in other neurodegenerative indications such as Parkinson's or Alzheimer's.
Background
BioVie is a clinical‑stage biotech focused on neuro‑inflammatory diseases; its Long COVID trial is part of a broader pipeline.
Ticker impact
BioVie disclosed new Phase 2 biomarker subgroup results for its Long COVID drug, the first public report of these findings.
likely pressure as investors weigh modest benefits against overall non‑significant trial outcomes
The data are new and materially affect expectations for the drug's path forward, but the mixed results limit upside.
Market effects
may temper enthusiasm for Long COVID therapeutics in biotech sector
limited to US biotech investors
low
Counterpoint
Investors could view the high‑inflammatory subgroup result as a catalyst for a future upside if further data confirm efficacy.
Key entities
- companyBioVie Inc.
Clinical‑stage biotech developing bezisterim for Long COVID and neurodegenerative diseases.
- institutionNational Institute of Allergy and Infectious Diseases (NIAID)
Co‑host of the RECOVER‑TLC workshop where data were presented.



